Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Three Times Is Enemy Action | Main | Spamming For Site Shutdowns. Sheesh. »

October 4, 2010

Sanofi Goes Hostile

Email This Entry

Posted by Derek

As of this morning. It looks like they were getting nowhere with Genzyme's board, so they're taking their same $69/share offer directly to the shareholders.

I'm not sure if that's going to be enough for them, but I presume that Sanofi-Aventis has already sounded out some of the institutional investors before going ahead. This isn't one of those questions you ask unless you're reasonably sure of the answer. But hostile bids do fail (or get their terms sweetened along the way). We've got until midnight, December 10, which is a long enough window for a lot of things to happen. Plenty of time to get some popcorn and find a good seat. . .

Comments (10) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. processchemist on October 4, 2010 8:47 AM writes...

This acquisition is causing a good amount of mess in the current activities of at least one Genzyme site. Whatever will happen, some damage is already done.

Permalink to Comment

2. taudeltaphenol on October 4, 2010 9:12 AM writes...

@#$%! Stupid, stupid, stupid.
Genzyme people aren't the only ones po'd about this.

Permalink to Comment

3. A Nonny Mouse on October 4, 2010 9:55 AM writes...

The BBC says that they have had a good response from shareholders, so it might go through.

http://www.bbc.co.uk/news/business-11464432

Permalink to Comment

4. Anonymous on October 4, 2010 6:46 PM writes...

I didn't realize that more scientists losing their jobs is now a spectator sport. Popcorn? How 'bout a little decorum?

Permalink to Comment

5. Anonymous on October 5, 2010 3:31 PM writes...

"I didn't realize that more scientists losing their jobs is now a spectator sport. Popcorn? How 'bout a little decorum?"

I didn't realize that inefficient companies with too many employees was a good thing.

Permalink to Comment

6. Hap on October 5, 2010 3:45 PM writes...

1) I didn't realize decorum could prevent mergers. If we would have known that about ten years ago, things in the pharma world would be a lot different, no?

2) The problem with mergers to improve efficiency is that you're supposed to actually be more efficient at doing something. Other than generating money for investment firms, what exactly has mergermania done for pharma? It certainly hasn't led to more drugs, and it doesn't seem too helpful for stockholders either (at least the ones that don't or can't sell out). If mergers are supposed to make companies more efficient, then when is that improvement supposed to show up?

Permalink to Comment

7. Anonymous on October 5, 2010 6:20 PM writes...

@6 Obviously decorum doesn't prevent hostile takeovers. Just suggesting that demonstrating some sensitivity towards those whose jobs are likely unable to survive might be more appropriate than equating the situation to a sporting event.

Permalink to Comment

8. anonymous on October 6, 2010 10:33 AM writes...

>>I didn't realize that inefficient companies with too many employees was a good thing.

Ah, please say that the day after you have been laid off, at 48, for being too inefficient as part of an inefficient company, or was replaced in favour of efficient 25-year olds from India or CHina.

Permalink to Comment

9. Hap on October 6, 2010 4:14 PM writes...

I would have figured "participants in a sporting event" would have been an improvement in status for the potential layoff victims than their current status as "cannon fodder", "money for my vacation home in Provence", or "cost center", at least in the eyes of S-A (and probably Genzyme) management.

In theory, losing jobs at Genzyme could be accompanied by gaining them elsewhere - the money locked up in Genzyme could be freed up to businesses that were actually effective, and decorum would be an irrelevant response. Unfortunately, pharma looks more and more like an instantiation of Atlas Shrugged with the moochers' roles being taken by large pharma executives, and there's no real hope that either the money will create jobs elsewhere, or that the incompetent management will be punished for their incompetence. Sympathy and decorum might be appreciated, but they're probably irrelevant.

Permalink to Comment

10. Anonymous on October 6, 2010 7:30 PM writes...

@9 Great theory...too bad it has no basis in current reality

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Novartis Impresses Where Others Have Failed
Exelixis Against the Wall
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening